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Abstract 
For decades, public communications about cancer screening have used 
persuasive techniques with the aim of maximising the number of people being 
screened. However, perspectives have changed more recently to acknowledge 
that screening can lead to harm as well as benefit, and that it is important for 
service users to consider both. For some types of cancer screening, there 
is professional contention about whether benefits clearly outweigh harms. 
In light of this, an emerging trend in cancer screening communication is to 
try to support informed decision making – that is, to help people understand 
both the advantages and disadvantages of screening, allowing them to 
make individual decisions about their screening participation that reflect their 
informed preferences. In this review, we provide an overview of key theoretical 
and practical aspects of improving communication and supporting informed 
decision making about cancer screening, highlight relevant research and discuss 
future implications.
Introduction
Cancer screening involves a complex array of potential consequences, 
including benefits (e.g. reduced disease burden, mortality and morbidity; 
improved disease outcomes) and harms (e.g. false positives, false negatives, 
overdiagnosis, other physical and psychological harms).1 There is variation 
across cancer types and screening modalities in the possible consequences for 
the individual screened, the probabilities of the various outcomes and the ratio 
of benefits to harms. These variations underpin differences in recommendations 
about whether and how screening should be offered and implemented. Some 
forms of screening are generally regarded as advantageous (e.g. bowel cancer 
screening with the faecal occult blood test); some are viewed more negatively 
(e.g. prostate cancer screening with prostate-specific antigen testing); and 
others are seen to have a finer balance between benefits and harms (e.g. breast 
cancer screening with mammography).2 Heterogeneity of study methodologies, 
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Key points
• Community views about cancer screening 
are very positive, which may be partly due 
to persuasive public communications
• Contemporary approaches are shifting 
towards the goal of enabling people to 
make informed decisions about their 
participation in screening
• Communication tools and methods such as 
decision aids and shared decision making 
can support people to make informed 
decisions about participating in screening
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population characteristics and screening delivery can 
lead to conflicting results and uncertainty about estimates 
of benefits and harms2, which complicate the task of 
making policy decisions about whether and how screening 
should occur. 
Despite these complexities, policy makers are 
increasingly seeking to enable informed decisions by 
providing balanced information on harms and benefits to 
potential screening participants.1 In this review, we give 
an overview of current research and practice relating 
to improving communication about cancer screening, 
including relevant examples across a range of contexts. 
At times, we focus on breast cancer screening as a case 
where communication issues have received intense 
attention in recent years.
Public perceptions of screening
Attitudes about cancer screening are highly positive among 
the general public, and screening is often supported 
uncritically.3-5 Qualitative research suggests that key 
reasons motivating people to undergo screening include 
taking responsibility for one’s own health, feeling a social 
obligation to do so, and gaining reassurance.3 A landmark 
US survey documented widespread public enthusiasm 
for routine cancer screening, with 87% of respondents 
considering it “almost always a good idea”.4 Very similar 
results were reported a decade later in a large British 
survey.5 People’s commitment to screening was strong 
enough that 58% of women in the US survey said they 
would overrule a physician who suggested having less 
frequent cervical screening, whereas 77% of men would 
continue prostate screening, and 74% of men and women 
would continue bowel screening even if their physician 
recommended against it.4 These attitudes may be based 
on unrealistic expectations: a systematic review of studies 
that quantitatively assessed patient or public expectations 
of medical interventions, including 15 studies on cancer 
screening, found that participants tended to overestimate 
benefits and underestimate harms.6
Conventional approach to providing 
information 
Public health messaging about cancer screening for many 
decades has largely reflected the positive views held by 
public health organisations, professional associations, 
patient advocacy groups, academics and clinicians.7 
According to these favourable perspectives on screening, 
authorities are justified in using persuasive communication 
tools with the goal of maximising uptake. These messages 
can take diverse forms. One frequently used approach is 
to induce feelings of fear and vulnerability, then offer hope 
by framing screening as a simple method of protection.7 
A common feature of many conventional approaches to 
screening communication is to emphasise benefits and 
minimise harms.2,7,8 For example, several international 
reviews (most recently by Gummersbach et al.9) have found 
that breast screening information materials overestimate 
benefits and underplay harms. Such communications have 
created highly positive community views of screening that 
engender normative expectations that screening is the 
‘right’ thing to do.3
Need for informed (shared) decision 
making
Messaging about screening has been criticised in recent 
years as simplistic and overly positive.2,7 It is argued that, 
rather than encouraging uptake, screening communication 
should aim to inform people about harms and benefits 
so that they can make informed decisions about 
participation.2,7 The ethical justification is that screening 
puts large numbers of healthy people at risk of possible 
harm by offering interventions they might not otherwise 
seek out.1 Advocates of this perspective note that screening 
can trigger a cascade of serious interventions with lasting 
consequences, and individuals who choose to screen (or 
not) must live with their decision and its repercussions. 
Individuals may weigh attributes differently depending 
on their personal circumstances and psychological 
characteristics – and some might reasonably decline 
screening.2 According to this perspective, screening 
decisions are a good example of the value of helping 
people be engaged and involved in decision making.
The terms ‘informed decision making’ and ‘shared 
decision making’ relate to public and patient involvement 
in healthcare decision making. Both terms encompass a 
process that enables a person to participate in making a 
healthcare decision, having learnt about the intervention 
and its likely consequences, and having considered their 
preferences. Shared decision making is conceptualised 
specifically in terms of patient–clinician consultations in 
which both parties express preferences and participate in 
making decisions. Shared decision making may therefore 
be more relevant to screening tests based in primary care 
(e.g. prostate cancer screening)10 than those provided 
outside a clinical encounter (e.g. breast and bowel cancer 
screening), where informed decision making might be the 
more appropriate term.
Supporting informed (shared) 
decision making with decision aids
Decision aids are designed to support people’s decision 
making about healthcare interventions in circumstances 
where more than one reasonable option is available, 
with benefits and harms that people value differently 
(i.e. where personal preferences are relevant).11 Decision 
aids make the decision explicit (e.g. to be screened or 
not), describe why the choice exists, provide information 
about options and their outcomes, and are intended to help 
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people consider the options from their own perspective. 
Randomised controlled trials in a variety of settings 
demonstrate that decision aids improve knowledge of 
risk and accuracy of risk perceptions, stimulate people to 
take a more active decision making role, and can improve 
congruence between personal values and the chosen 
option, usually without lengthening consultations.11 Decision 
aids can also assist informed decision making about 
screening participation.12
Uncertainties about the level of benefit and harm can 
make it difficult to determine what specific information 
to provide in decision support materials about cancer 
screening. Selecting the most appropriate data involves 
considering both the methodological quality of the evidence 
and its relevance to the local context. For transparency 
and to reduce bias, decision aids (or supplementary 
documents that describe their development) should cite 
the studies selected.13 When presenting quantitative 
information (e.g. frequencies of benefits and harms), risk 
communication research supports using either percentages 
(e.g. x%) or frequency formats (e.g. x in 1000) and 
specifying the denominator.14 Pictographs or icon arrays 
(e.g. as used by Smith et al.15 and Hersch et al.16) improve 
comprehension, including among people with low literacy 
and numeracy.14 Given that there is rarely any single ‘right’ 
number for a specific outcome probability, decision aids 
should also try to communicate the scientific uncertainty in 
some way (e.g. as described by Forbes and Ramirez17).13
There are some concerns that encouraging laypeople 
to take a more active role in healthcare decisions might 
exacerbate inequalities. To examine this, a systematic 
review evaluated the impact of shared decision making 
interventions on health inequalities, including nine studies 
about cancer screening.18 The review concluded that 
such interventions significantly improve outcomes for 
disadvantaged groups18, which suggests that a shared 
decision making approach for cancer screening is likely to 
be broadly beneficial, including for vulnerable populations. 
For example, an Australian trial of a bowel cancer screening 
decision aid for adults with low education15 achieved an 
85% consent rate in a socio-economically disadvantaged 
population, with 93% of those randomised completing the 
trial. The decision aid increased the proportion of people 
making an informed choice by 22% (as per the study 
definition)15, providing evidence that informed decision 
making can be accessible to the wider community.
Alternative approaches
Although structured presentation of health information may 
empower people to assume a more active decision making 
role, some people may not wish to personally evaluate 
detailed screening information.17 Furthermore, despite 
considerable research evidence supporting decision aids11, 
integrating shared decision making into routine clinical 
practice continues to be a challenge.19 Alternatives include 
the ‘consider an offer’ approach, which aims to avoid 
overburdening people with unwanted information and tasks 
while respecting their autonomy8, and has been the basis 
for the approach to cancer screening communication in 
England since 2013.17 The model involves helping people 
evaluate the trustworthiness and personal relevance of the 
screening offer, acknowledging that it might reasonably be 
declined, and making further information available for those 
who want it. People who are eligible for cancer screening 
receive a letter of invitation from the National Health Service 
(which may be seen as a recommendation in itself), and 
a leaflet (developed at arm’s length from the screening 
program) that provides more information about benefits 
and harms. The leaflet aims to encourage people to assess 
the offer of screening, rather than simply encouraging 
screening, and to make it clear that declining the offer may 
be justified.17
Ultimately, whether individual-level deliberation is to 
be promoted for a given healthcare decision is a policy 
judgement. Such judgements can be usefully guided by 
evidence on the preferences of well-informed members 
of the public. Engaging a ‘community jury’ (or ‘citizens’ 
jury’), in which a representative sample of the target 
population deliberates together about benefits and harms, 
has been demonstrated to be a feasible way of eliciting 
an informed, considered community view on questions 
of screening policy and communication. For example, an 
Australian community jury about prostate cancer screening 
concluded that men should be able to make informed 
choices, identified the need for better information, and 
recommended supporting general practitioners to better 
inform patients.10 This method has also been applied in the 
context of breast cancer screening.17
Communicating about 
overdiagnosis
One particularly contentious issue in some cancer 
screening contexts is overdiagnosis (or overdetection). A 
prominent concern in prostate, thyroid and breast cancer 
(with evidence emerging about lung cancer), overdiagnosis 
occurs when tumours are detected that would not become 
clinically apparent or cause death if left undetected and 
untreated. There is currently no way to reliably determine 
whether a given cancer will progress or remain indolent, so 
overdiagnosis typically leads to overtreatment, even among 
screen-detected cases that are recognised as low risk 
(e.g. low-grade prostate cancer).
Much of the shift in perspective towards promoting 
informed choice over increased uptake has been due 
to increasing concern about overdiagnosis, especially 
in breast cancer screening.17 Public awareness about 
overdiagnosis of slow-growing cancers is limited.10,17,20 An 
online survey of people aged 50–69 in the US who had 
been invited to participate in cancer screening by their 
doctor found that less than 10% of patients had been 
informed about the risk of overdiagnosis.21 Similarly, in 
an Australian telephone survey, 10% of women and 18% 
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of men who had been screened for breast and prostate 
cancer, respectively, said they were told about the risk 
of overdiagnosis.22
Communicating the concept of overdiagnosis is 
difficult, partly because it is undetectable on an individual 
level, which means that understanding it is not intuitive. A 
randomised controlled trial in Australia aimed to improve 
women’s understanding about overdiagnosis in breast 
cancer screening and assessed the effects of informing 
them.16 The decision aid explaining overdiagnosis increased 
knowledge and enabled more women to make an informed 
choice (as per the study definition), compared with a 
control decision aid omitting this information. Being better 
informed about potential consequences also made women 
feel slightly less positive about breast cancer screening 
and somewhat reduced intentions to be screened. This 
suggests that some women, when better informed, might 
make different decisions about participation.16 Similarly, a 
brief explanation of overdiagnosis reduced intentions to 
undergo thyroid cancer screening among Korean women.20
Communication in context
Crucially, evidence based information such as that 
presented in a decision aid is just one of many factors 
shaping healthcare choices. Decisions are influenced by 
emotions, not only scientific information. People’s sense 
of risk is often more about feelings than facts, which 
might limit the impact of new factual information.23 Breast 
cancer screening, in particular, has been highlighted as a 
decision context exemplifying the tension between powerful 
emotions and objective risk assessment.23 This tension 
makes it challenging to communicate potential harms of 
screening.
The source of information may shape how individuals 
interpret new information. Clinicians tend to be respected 
as credible sources of advice and can influence public 
perceptions of cancer screening.24 If future information 
materials encourage more deliberative decision making, 
clinicians might be called on to help people understand the 
evidence and guide them in clarifying their preferences. 
Current evidence suggests that many clinicians perform 
suboptimally in explaining the downside of screening to 
patients.25 Clinicians may not yet have the capacity or 
training to participate usefully in shared decision making 
about screening, and messages currently conveyed by 
clinicians may be inconsistent with recently developed 
screening information.17 An important future goal should 
therefore be to develop ways to support clinicians in 
communicating more effectively with patients about 
cancer screening, and its benefits and harms, including 
overdiagnosis and other challenging topics.10
Conclusion
When communicating with the public about cancer 
screening, promoting uptake by emphasising benefits was 
once considered justified. However, for some types of 
cancer screening, there is professional contention about 
whether the benefits of screening clearly outweigh the 
harms. Arguments have been made that individuals should 
be supported to make informed decisions about whether to 
undergo screening, and that they need accessible, high-
quality information about screening outcomes to do so. 
Despite challenges, research has shown that it is 
possible to help people become better informed about 
screening.10,12,16 Based on recent evidence16,20, it appears 
that most people would still prefer to be screened, 
even when given new information about risks such as 
overdiagnosis. Engaging and supporting individuals to 
construct and enact their own informed preferences 
in making decisions about their healthcare is vital if 
patients and citizens are really to be at the heart of the 
healthcare system.
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